In this observational safety study, a team of scientists from the Danish Multiple Sclerosis Center and the Department of Neurology at the University of Copenhagen, Denmark, monitored 28 patients with multiple sclerosis (MS).
They were treated with medical cannabis oils (THC-rich, CBD-rich and THC+CBD in equilibrium). The average dose was 4 milligrams for THC and 7 mg for CBD. The patients were undergoing neurological and other examinations during the four-week treatment.
Pain decreased from average 7 to 4 points on the NRS-11 numeric rating scale, spasticity from 6 to 2.5 pts, and sleep disturbances from 7 to 3 pts, on average.
Treatment with medical cannabis oils was safe and well tolerated, and resulted in a reduction in pain intensity, spasticity and sleep disturbances in MS patients.
Side effects (dry mouth, drowsiness, dizziness, nausea) were reported when using the THC-rich oil but evaluated as moderate.
The authors of the study came to the conclusion that “treatment with medical cannabis oils was safe and well tolerated, and resulted in a reduction in pain intensity, spasticity and sleep disturbances in MS patients. This suggests that medical cannabis oils can be used safely, especially at relatively low doses and with slow titration, as an alternative to treat MS-related symptoms when conventional therapy is inadequate.”
Author: Tibor Béres
Source: Cannabis Therapy Vol. 2
Take a quick look at this preview of the contents: